Related Experiment Video
Updated: May 1, 2026
Bioluminescent Optogenetics 2.0: Harnessing Bioluminescence to Activate Photosensory Proteins In Vitro and In Vivo
Published on: August 4, 2021
Illuminating cancer therapy: The translational path of optogenetics
Bing Yang1, Qiyi Feng1, Chunxiu Xiao1
1Laboratory of Precision Therapeutics, Department of Pulmonary and Critical Care Medicine, Institute of Respiratory Health and Multimorbidity, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China.
Abstract:
Tumor recurrence, metastasis, and therapeutic resistance remain major challenges in oncology, driving the need for advanced therapeutic strategies with improved precision and controllability. Optogenetics, which enables light-mediated regulation of cellular functions, has emerged as a promising modality for cancer therapy by offering unparalleled spatiotemporal precision. This capability allows dynamic control of intracellular signaling and transgene expression, enabling selective targeting of malignant cells while minimizing damage to surrounding tissues. However, clinical translation is hindered by key challenges, including inefficient in vivo delivery of optogenetic components, limited tissue penetration of activating light, and suboptimal performance of existing tools. Addressing these barriers requires a convergence of molecular engineering and materials science, wherein advanced biomaterials play a critical role in enabling gene delivery and overcoming tissue-penetration limitations in complex tumor environments. In this review, we provide a comprehensive oriented overview of optogenetics in oncology. We first analyze the molecular mechanisms and engineering principles of representative optogenetic tools, with a focus on LOV- and CRY2-based systems. We then highlight recent advances in biomaterial-assisted optogene delivery and light delivery strategies, emphasizing their material-dependent mechanisms that enable precise spatiotemporal control in vivo. Furthermore, we summarize emerging preclinical applications in cancer immunotherapy, gene regulation, and intracellular signaling control. Finally, we discuss key challenges in biosafety, kinetic optimization, and clinical scalability, and outline future directions that integrate optogenetics with functional materials and intelligent design to realize clinically viable platforms. This review aims to provide a framework for the development of clinically viable optogenetic platforms for next-generation cancer therapy.
Insights
Optogenetics offers precise, light-controlled cancer therapy by regulating cellular functions. Biomaterials enhance optogene delivery and light penetration for improved in vivo cancer treatment strategies.
Area of Science:
- Oncology
- Biomedical Engineering
- Molecular Biology
Background:
- Tumor recurrence, metastasis, and therapeutic resistance are significant challenges in cancer treatment.
- Optogenetics provides spatiotemporal precision for regulating cellular functions, offering a promising approach for targeted cancer therapy.
- Current limitations include inefficient in vivo delivery, poor light penetration, and suboptimal tool performance.
Purpose of the Study:
- To provide a comprehensive overview of optogenetics in oncology.
- To analyze molecular mechanisms and engineering principles of optogenetic tools (LOV- and CRY2-based systems).
- To highlight advances in biomaterial-assisted optogene and light delivery for precise in vivo control.
Main Methods:
- Review of molecular mechanisms and engineering principles of optogenetic tools.
- Analysis of biomaterial-assisted strategies for optogene and light delivery.
- Summary of preclinical applications in cancer immunotherapy, gene regulation, and intracellular signaling.
Main Results:
- Optogenetic tools, particularly LOV- and CRY2-based systems, offer precise spatiotemporal control.
- Biomaterials are crucial for overcoming in vivo delivery and light penetration challenges.
- Emerging preclinical applications demonstrate potential in immunotherapy and gene regulation.
Conclusions:
- Optogenetics holds significant promise for next-generation cancer therapy.
- Integration with functional materials and intelligent design is key to clinical viability.
- Addressing challenges in biosafety, kinetics, and scalability is essential for translation.
